For gene therapy programs entering Phase 3, regulatory scrutiny intensifies on long-term safety and vector biodistribution. Monitoring adeno-associated virus (AAV) vector shedding in blood via quantitative PCR (qPCR) is a primary method for assessing systemic vector clearance and persistence. Generating robust, long-term shedding data is a required component of the safety database for a Biologics License Application (BLA) submission, directly informing risk assessment and product labeling.

What is the primary objective of long-term AAV shedding analysis in Phase 3?

A: The main goal is to characterize the clearance kinetics and long-term persistence of the AAV vector in systemic circulation. This data is fundamental to the integrated summary of safety for regulatory submissions and helps define the duration of potential risk for horizontal transmission.

Which sample matrix is most relevant for systemic AAV shedding?

A: Whole blood, plasma, and serum are the primary matrices. Blood provides a direct measure of systemically circulating vector DNA, offering a clear window into the vector’s clearance profile following administration. Urine and saliva are also commonly collected to assess other routes of excretion.

What is the typical duration for monitoring in late-stage trials?

A: Monitoring duration is protocol-specific and guided by preclinical data and early clinical findings. For Phase 3, it is common to see collection time points extending from several months to over a year post-administration to establish a definitive clearance curve and confirm when levels fall below the limit of detection.

How does qPCR sensitivity impact data interpretation?

A: The lower limit of quantification (LLOQ) of the validated qPCR assay is a key parameter. A highly sensitive assay is required to accurately track the terminal clearance phase of the vector. This precision ensures that the absence of a signal is a reliable indicator of clearance, not a limitation of the assay itself.

GxP-Compliant Bioanalytical Support for Pivotal Trials

Executing these long-term studies requires a robust bioanalytical framework. Franklin Biolabs develops and validates sensitive, product-specific qPCR assays under GxP conditions to support pivotal clinical trials. Our >100,000 sq ft facility is equipped to handle high-throughput sample analysis, ensuring data integrity and timely reporting for programs targeting IND submission within 18-24 months.

)

Our approach is built on deep scientific expertise and a collaborative model that aligns with the specific objectives of your clinical program. This commitment to partnership ensures that the bioanalytical strategy is scientifically sound and regulatory-compliant from the outset.

“We started collaborating with UPenn Vector core in 2023 and the AAV vector which they manufactured laid a foundation for development of a gene therapy candidate which will enter soon preclinical studies. The key people from UPenn Vector Core joined Franklin Biolabs and our partnership transitioned without interruption from UPenn Vecor Core to Franklin Biolabs Research Vector Division. Franklin Biolabs is our trusted partner in our AAV-vector based gene therapy candidate development and we hope to continue the partnership for years to come.”
— Biotech Partner